Several human studies conducted on patients with cognitive impairments, including AD, have found that high BACE1 concentrations and activity in the CSF, serum, or plasma are associated with impairments in cognitive functions, as well as neuroimaging features, and brain changes in AD [26–32]. This evidence concerns the gene BACE1 and Alzheimer disease.